idiopath
pulmonari
fibrosi
ipf
chronic
progress
interstiti
fibrot
lung
diseas
character
chronic
lung
inflamm
disrupt
alveolar
structur
interstiti
fibroblast
prolifer
excess
extracellular
matrix
synthesi
deposit
although
evid
show
persist
inflammatori
respons
associ
progress
develop
ipf
therapi
current
use
ipf
name
antiinflammatori
immunosuppress
drug
larg
ineffect
therefor
novel
therapi
capabl
target
inflamm
without
compromis
bodi
immun
still
challeng
area
macrophag
lung
tissu
play
import
role
clearanc
pulmonari
pathogen
steadyst
homeostasi
mainten
emerg
evid
suggest
causal
link
lung
macrophag
mediat
inflamm
excess
tissu
destruct
elicit
varieti
exogen
stimuli
ie
silica
asbesto
exposur
viru
infect
etc
ultim
lead
failur
inflamm
resolut
key
featur
progress
promot
develop
lung
fibrosi
hand
macrophag
cell
popul
high
plastic
display
function
divers
differ
stage
inflammatori
respons
activ
state
macrophag
gener
character
classic
activ
polar
associ
immun
respons
altern
activ
polar
associ
immun
respons
lung
tissu
macrophag
first
line
defens
acut
lung
injuri
later
replac
macrophag
contribut
tissu
repair
fibrosi
gener
believ
inflamm
myeloid
monocyt
contribut
lung
macrophag
replenish
result
recent
basic
studi
indic
manipul
macrophag
phenotyp
switch
might
potenti
target
mani
macrophag
mediat
disord
recent
usher
colleagu
demonstr
macrophag
mice
lack
myeloid
mineralocorticoid
receptor
mr
exhibit
transcript
profil
mimic
altern
activ
macrophag
protect
angiotensin
ii
angii
induc
cardiac
hypertrophi
fibrosi
work
provid
evid
indic
mr
mononuclear
phagocyt
might
potenti
target
therapeut
purpos
base
current
evid
specul
pharmacolog
inhibit
mr
clinic
approv
drug
may
regul
lung
macrophag
phenotyp
switch
well
progenitor
bone
marrowderiv
circul
monocyt
may
confer
novel
therapeut
potenti
murin
model
bleomycininduc
acut
pulmonari
injuri
fibrosi
eight
ten
week
male
mice
weigh
purchas
laboratori
anim
center
academi
militari
medic
scienc
beij
china
anim
receiv
human
care
complianc
regul
manag
experiment
anim
tianjin
municip
scienc
technolog
commiss
revis
june
accord
guid
care
use
laboratori
anim
publish
nation
institut
health
nih
pub
revis
experiment
procedur
perform
author
anim
use
care
committe
logist
univers
chines
peopl
arm
polic
forc
valid
mrna
express
mr
mous
circul
monocyt
circul
monocyt
mice
purifi
peripher
blood
use
magnet
beadbas
kit
easyseptm
mous
monocyt
enrich
kit
cat
stemcel
technolog
vancouv
bc
canada
puriti
enrich
monocyt
confirm
flow
cytometri
see
detail
method
total
rna
isol
revers
transcript
realtim
pcr
analysi
shown
valid
protein
express
mr
circul
monocyt
alveolar
macrophag
purifi
monocyt
cell
bronchoalveolar
lavag
fluid
balf
seed
glass
slide
immunohistolog
detect
mr
briefli
cell
fix
methanol
follow
permeabil
triton
cell
incub
primari
antimous
mineralocorticoid
receptor
monoclon
antibodi
abcam
cambridg
usa
overnight
ensur
specif
isotyp
control
prepar
alveolar
macrophag
cell
incub
primari
antimous
antibodi
abcam
h
wash
pb
cell
incub
tetramethylrhodamin
isothiocyan
tritc
conjug
goat
antimous
secondari
antibodi
alveolar
macrophag
fluorescein
isothiocyan
fitc
conjug
goat
antirat
secondari
antibodi
also
ad
dark
cell
nuclei
stain
dapi
sigmaaldrich
st
loui
mo
usa
light
protect
imag
visual
fluoresc
microscop
eclips
nikon
tokyo
japan
unstain
sampl
sampl
stain
secondari
antibodi
without
incub
primari
antibodi
use
neg
control
show
signal
analysi
induc
pulmonari
fibrosi
mice
lightli
anesthet
inhal
ether
bleomycin
bodi
weight
salin
salin
administ
oropharyng
instil
describ
previous
anim
randomli
alloc
four
treatment
group
normal
salin
ns
bleomycin
blm
bleomycin
plu
normal
salin
blmn
bleomycin
plu
spironolacton
blmsp
day
administr
day
vehicl
salin
sp
dissolv
salin
deliv
oral
gavag
daili
continu
day
day
anim
sacrif
exsanguin
sodium
pentobarbit
anesthesia
mice
time
point
blood
balf
lung
tissu
collect
follow
assay
balf
collect
intratrach
cannula
three
sequenti
ml
steril
salin
centrifug
g
min
cellfre
supernat
store
analysi
cytokin
cell
pellet
resuspend
steril
salin
total
cell
count
differenti
cell
count
immunohistochem
stain
flow
cytometri
analysi
left
lung
balf
harvest
fix
paraformaldehyd
solut
embed
paraffin
section
prepar
stain
hematoxylineosin
masson
trichrom
examin
light
microscop
nikon
tokyo
japan
detect
myofibroblast
smooth
muscl
actin
sigmaaldrich
st
loui
mo
usa
immunofluoresc
stain
carri
previous
describ
evalu
inflammatori
respons
induc
bleomycin
semiquantit
score
criteria
szapiel
cowork
use
blind
fashion
fibrosi
collagen
determin
nonoverlap
field
use
digit
quantit
analysi
imag
pro
plu
softwar
version
media
cybernet
silver
spring
md
usa
lung
fibrosi
index
defin
sum
total
area
collagen
entir
visual
field
divid
sum
total
connect
tissu
area
entir
visual
field
collagen
content
whole
left
lung
determin
analysi
hydroxyprolin
previous
describ
brief
lung
lobe
homogen
ml
phosphat
buffer
salin
pb
hydrolyz
ml
n
hydrochlor
acid
hour
neutral
ph
naoh
chloramin
reagent
ml
moll
ad
sampl
left
room
temperatur
minut
pdimethylaminobenzaldehyd
solut
dissolv
n
perchlor
acid
ad
sampl
mixtur
incub
minut
absorb
measur
nm
nanodrop
spectrophotomet
thermo
scientif
waltham
usa
cell
blood
balf
lung
subject
flow
cytometri
analysi
cytom
cytomet
beckman
coulter
miami
fl
usa
antibodi
obtain
biolegend
san
diego
ca
usa
data
analyz
flowjo
softwar
treestar
ashland
usa
valid
puriti
magnet
beadenrich
circul
monocyt
antimous
phycoerythrin
pe
clone
antimous
clone
use
analysi
circul
monocyt
subset
ethylenediaminetetraacet
acid
edta
anticoagul
whole
blood
stain
antimous
phycoerythrin
pe
clone
antimous
clone
incub
min
room
temperatur
dark
follow
red
cell
lysi
sampl
analyz
immunophenotyp
analysi
alveolar
macrophag
cell
isol
balf
first
centrifug
min
g
room
temperatur
supernat
discard
remov
dead
cell
flow
cytometri
analysi
cell
first
suspend
trypan
blue
pb
number
live
dead
cell
measur
use
automat
cell
counter
counterstartm
rui
yu
biotechnolog
co
ltd
shanghai
china
method
number
live
cell
sampl
subsequ
flow
cytometri
analysi
cell
incub
antimous
clone
antimous
clone
antimous
clone
follow
incub
flow
cytometri
analysi
carri
immunophenotyp
analysi
interstiti
macrophag
im
lung
singlecel
suspens
prepar
lavag
lung
balf
harvest
reduc
contamin
brief
lower
lobe
right
lung
minc
incub
mgml
collagenas
solut
type
sigmaaldrich
min
filter
nylon
mesh
similar
procedur
remov
dead
cell
carri
sampl
prepar
analysi
cell
suspens
stain
antimous
clone
antimous
clone
antimous
clone
follow
incub
sampl
analyz
flow
cytomet
isotyp
antibodi
clone
clone
clone
clone
clone
clone
use
detect
nonspecif
bind
gate
strategi
analyz
im
accord
previou
report
total
rna
purifi
blood
monocyt
lung
tissu
isol
use
trizol
reagent
invitrogen
carlsbad
ca
usa
accord
manufactur
instruct
total
rna
reversetranscrib
cdna
use
revers
transcript
assay
promega
madison
wi
usa
reaction
volum
accord
manufactur
instruct
realtim
pcr
perform
sybr
green
pcr
master
mix
roch
diagnost
indianapoli
usa
abi
prism
sequenc
detect
system
appli
biosystem
foster
citi
ca
usa
triplic
accord
twostep
pcr
protocol
min
cycl
min
primer
sequenc
shown
tabl
rel
express
realtim
pcr
product
normal
express
express
transcript
fold
chang
ns
mice
use
method
level
transform
growth
factor
monocyt
chemoattract
chemokin
cc
motif
ligand
balf
measur
commerci
avail
elisa
kit
r
system
minneapoli
mn
usa
accord
manufactur
instruct
data
present
mean
standard
error
mean
sem
statist
analysi
perform
use
graphpad
prism
softwar
graphpad
san
diego
ca
usa
statist
comparison
multipl
group
perform
oneway
anova
bonferroni
posthoc
test
kruskalw
test
follow
dunn
multipl
comparison
inflamm
score
fibrosi
index
twotail
p
valu
less
consid
statist
signific
use
magnet
beadbas
monocyt
enrich
method
harvest
cell
figur
confirm
mr
mrna
express
cell
realtim
pcr
pcr
product
electrophoresi
figur
mr
protein
express
enrich
monocyt
valid
immunofluoresc
stain
figur
use
mous
balf
also
confirm
mr
express
alveolar
macrophag
figur
result
suggest
mr
express
mous
mononuclear
phagocyt
provid
basi
pharmacolog
intervent
figur
show
detail
research
protocol
vivo
pharmacolog
intervent
studi
figur
h
show
repres
stain
lung
section
day
repres
peak
magnitud
lung
inflammatori
respons
follow
bleomycin
instil
spironolacton
treatment
could
significantli
reduc
inflammatori
respons
induc
bleomycin
figur
panel
j
figur
show
result
differenti
cell
count
balf
harvest
day
typic
total
fluid
recoveri
anim
percentag
fluid
recov
significantli
differ
across
treatment
group
agreement
histolog
find
spironolacton
treat
lung
exhibit
decreas
total
cell
macrophag
lymphocyt
neutrophil
infiltr
esosinophil
alveoli
next
measur
level
inflammatori
profibrot
cytokin
balf
determin
relat
gene
express
level
lung
tissu
shown
figur
compar
blm
blmn
group
spironolacton
treatment
associ
downregul
mrna
protein
level
addit
marker
polar
mrna
level
lung
tissu
figur
protein
content
balf
figur
downregul
spironolacton
figur
show
profibrot
respons
use
lung
tissu
harvest
day
histolog
analysi
show
mr
antagon
associ
reduc
collagen
deposit
posit
cell
myofibroblast
compar
ns
group
express
type
type
iii
collagen
mrna
lung
blm
blmn
group
significantli
upregul
wherea
spironolacton
treatment
could
partial
regress
bleomycininduc
collagen
express
upregul
consist
histolog
find
next
evalu
effect
spironolacton
treatment
circul
monocyt
subset
chang
figur
show
gate
strategi
circul
monocyt
subset
analysi
shown
figur
compar
ns
group
blm
treat
mice
exhibit
signific
increas
monocyt
start
day
reach
plateau
level
day
follow
gradual
decreas
till
day
spironolacton
treatment
could
significantli
reduc
bleomycininduc
monocyt
pool
expans
day
thereaft
reciproc
chang
monocyt
subset
shown
figur
use
enzymat
digest
lung
tissu
evalu
interstiti
macrophag
phenotyp
chang
drug
intervent
shown
figur
one
day
bleomycin
challeng
major
interstiti
macrophag
present
phenotyp
follow
gradual
decreas
trend
proport
macrophag
trend
reach
statist
differ
day
moreov
compar
blm
blmn
group
spironolacton
obviou
influenc
interstiti
macrophag
phenotyp
switch
induc
bleomycin
investig
impact
spironolacton
alveolar
macrophag
phenotyp
chang
shown
figur
alveolar
macrophag
ns
group
mainli
present
phenotyp
bleomycin
challeng
quick
decreas
macrophag
concomit
increas
phenotyp
wherea
spironolacton
treat
mice
trend
partial
normal
indic
inhibitori
effect
altern
activ
mr
antagon
recent
studi
show
renin
angiotensin
aldosteron
system
raa
play
import
role
pathogenesi
lung
injuri
addit
therapeut
efficaci
drug
intervent
target
system
report
bleomycininduc
lung
injuri
model
zhao
cowork
first
demonstr
therapeut
potenti
spironolacton
amelior
bleomycininduc
lung
fibrosi
also
support
recent
studi
grow
bodi
evid
suggest
manipul
mononuclear
phagocyt
phenotyp
switch
could
feasibl
approach
alter
sever
persist
pulmonari
injuri
fibrosi
experiment
model
demonstr
mr
play
import
role
regul
myeloid
cell
phenotyp
switch
differ
diseas
condit
knowledg
role
mononuclear
cell
mr
mediat
acut
lung
injuri
induc
pulmonari
fibrosi
address
present
work
confirm
mr
antagon
clinic
approv
drug
spironolacton
could
attenu
bleomycininduc
acut
lung
injuri
fibrosi
specif
mr
inhibit
partial
attenu
monocyt
expans
circul
compart
normal
disturb
balanc
macrophag
polar
alveolar
compart
lead
reduc
alveol
collagen
deposit
lung
tissu
find
highlight
mononuclear
phagocyt
mr
promis
target
amelior
acut
lung
injuri
profibrot
respons
lung
raa
hormon
system
act
multipl
physiolog
pathway
regul
blood
pressur
fluid
balanc
termin
effector
raa
cascad
role
aldosteronemr
signal
recent
implic
pathogenesi
cardiovascular
diseas
insulin
resist
diabet
chronic
inflamm
associ
fibrosi
effect
support
fact
addit
kidney
wide
tissu
distribut
mr
cardiomyocyt
endotheli
cell
vascular
smooth
muscl
cell
adipocyt
macrophag
demonstr
mr
express
purifi
murin
circul
monocyt
alveolar
macrophag
provid
basi
mr
regul
monocytemacrophag
phenotyp
switch
macrophag
profession
phagocyt
cell
differ
transcript
profil
function
capabl
depend
origin
variou
organ
broadli
speak
lung
tissu
contain
two
tissueresid
macrophag
compart
ie
alveolar
macrophag
interstiti
macrophag
tradit
belief
tissueresid
macrophag
deriv
circul
monocyt
progenitor
challeng
recent
fate
map
studi
show
steadyst
turnov
alveolar
macrophag
extrem
low
month
bone
marrow
transplant
alveolar
macrophag
host
deriv
addit
recent
studi
demonstr
lung
alveolar
macrophag
establish
prior
birth
maintain
subsequ
adulthood
independ
replenish
circul
monocyt
input
steadi
state
contrari
acut
lung
inflammatori
respons
circul
monocyt
import
impact
lung
macrophag
dynam
gener
recent
studi
agreement
notion
follow
injuri
increas
accumul
mononuclear
cell
alveoli
moreov
patient
chronic
obstruct
pulmonari
diseas
skew
alveolar
macrophag
phenotyp
observ
howev
regard
origin
cell
controversi
exist
endotoxininduc
lung
inflamm
model
mau
cowork
show
despit
rapid
recruit
monocyt
lung
tissu
resid
alveolar
macrophag
pool
remain
static
throughout
durat
inflamm
expans
lung
macrophag
pool
mainli
mediat
influx
circul
monocyt
follow
differenti
tissu
macrophag
agreement
find
recent
osterholz
et
al
use
genetarget
alveolar
injuri
model
demonstr
increas
exud
macrophag
progenitor
monocyt
exhibit
polar
alveoli
anoth
studi
gibbon
colleagu
adopt
transfer
monocyt
bleomycintr
mice
progress
phase
lung
fibrosi
led
exacerb
diseas
progress
increas
accumul
macrophag
lung
surprisingli
altern
activ
macrophag
host
deriv
donor
monocyt
corollari
regardless
origin
current
knowledg
point
gener
scheme
relationship
initi
acut
lung
injuri
induc
rapid
expans
infiltr
monocyt
lung
tissu
contribut
parallel
increas
macrophag
direct
differenti
paracrin
effect
alveolar
compart
sever
persist
polar
alveolar
macrophag
would
ultim
influenc
inflamm
resolut
fibrosi
model
highlight
circul
monocyt
therapeut
target
although
use
monocytetarget
approach
suppress
monocytosi
like
spironolacton
would
also
exert
major
pharmacolog
effect
circul
monocyt
pool
sinc
efficaci
oral
administ
drug
significantli
compromis
inabl
reach
alveolar
space
appropri
concentr
addit
evid
shown
monocyt
infiltr
would
facilit
alveolar
neutrophil
emigr
determin
ongo
neutrophil
influx
persist
phase
acut
lung
injuri
suppress
monocytosi
spironolacton
would
concomitantli
lead
decreas
tissu
accumul
neutrophil
also
observ
studi
present
work
follow
limit
first
spironolacton
antiandrogen
effect
observ
effect
work
total
ascrib
mr
antagon
inde
sex
discrep
bleomycininduc
lung
fibrosi
estrogen
may
protect
effect
model
regard
mr
knockout
mice
prefer
address
issu
second
observ
signific
chang
lung
interstiti
macrophag
spironolacton
previou
studi
show
popul
might
role
limit
inflamm
fibrosi
thu
remain
unclear
whether
appropri
marker
popul
recent
studi
show
chang
modest
bleomycin
challeng
popul
insensit
mr
inhibit
due
enzymat
digestioninduc
surfac
marker
loss
sampl
prepar
commonli
encount
technic
issu
third
due
wide
distribut
mr
bodi
mechanist
explan
global
mr
antagon
fairli
complex
exampl
aldosteron
implic
pathogenesi
pulmonari
hypertens
spironolacton
shown
attenu
experiment
pulmonari
hypertens
via
mr
inhibit
pulmonari
arteri
smooth
muscl
cell
admittedli
bleomycin
also
frequent
use
tool
drug
induc
pulmonari
hypertens
downregul
spironolacton
observ
studi
also
support
antifibrot
effect
spironolacton
fibroblast
moreov
function
express
mr
demonstr
neutrophil
may
also
particip
spironolacton
induc
amelior
lung
fibrosi
shown
reduc
neutrophil
count
balf
thu
addit
effect
mononuclear
phagocyt
mechan
underli
therapeut
effect
system
use
spironolacton
bleomycininduc
lung
injuri
multifactori
forth
seem
obscur
interpret
effect
mr
antagon
alveolar
macrophag
polar
sinc
macrophag
lack
myeloid
mr
exhibit
altern
activ
polar
wherea
result
show
mr
inhibit
could
reduc
alveolar
polar
note
longestablish
binari
classif
macrophag
term
classic
altern
activ
base
vitro
studi
inde
recent
studi
demonstr
eplerenon
anoth
clinic
approv
mr
antagonist
promot
altern
activ
human
monocytederiv
macrophag
howev
macrophag
vivo
maintain
plastic
alter
phenotyp
base
microenviron
includ
cytokin
milieu
among
factor
point
earli
drug
administr
via
oral
rout
reach
alveolar
space
appropri
concentr
therefor
alter
alveolar
macrophag
polar
state
ascrib
mr
antagonist
direct
effect
conceiv
suppress
inflammatori
subset
monocyt
expans
direct
effect
spironolacton
amelior
lung
injuri
via
direct
pulmonari
alter
activ
mechan
thu
futur
monocytetarget
approach
well
vitro
studi
warrant
elucid
molecular
mechan
underli
suppress
monocytosi
mr
antagon
final
algorithm
use
studi
rel
simpl
may
inadvert
contain
dendrit
cell
eosinophil
rigor
sophist
algorithm
publish
suggest
conclus
present
work
provid
experiment
evid
mr
antagon
spironolacton
could
attenu
bleomycininduc
acut
pulmonari
injuri
fibrosi
partial
reduc
circul
inflammatori
monocyt
expans
inhibit
altern
activ
mononuclear
phagocyt
alveolar
compart
find
highlight
mr
potenti
therapeut
target
inhibit
monocytemedi
inflammatori
respons
acut
lung
injuri
fibrosi
